Glenmark enters collaboration and distribution agreement with Jiangsu Hansoh Pharma for Aumolertinib, a third-generation GFR-TKI to treat NSCLC: Our Bureau, Mumbai Wednesday, Dece ...
Glenmark inks deal with Hansoh Pharma to commercialize Aumolertinib, a lung cancer drug, in key global markets. Potential USD ...
AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that ...
Amgen receives US FDA approval for Uplizna to treat Adults with generalized myasthenia gravis: Thousand Oaks, California Saturday, December 13, 2025, 11:00 Hrs [IST] Amgen announc ...
NDTV Profit on MSN
Glenmark Inks Licensing Pact With China's Hansoh Pharma For Cancer Drug
Hansoh Pharma will receive an upfront payment of low double-digit million dollars, followed by potential regulatory and ...
Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...
As of Tuesday, December 16, Relay Therapeutics, Inc.’s RLAY share price has surged by 6.25%, which has investors questioning ...
Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...
Under the agreement, Glenmark has received exclusive rights to develop and commercialise Aumolertinib across its licensed territories, which include the Middle East and Africa, Southeast and South ...
Stocks to Watch today, December 17, 2025: Indian equity markets are anticipated to open flat on Wednesday, December 17, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results